CSIMarket Company Name, Ticker, Competitors, else..
 
Liminatus Pharma Inc   (NASDAQ: LIMN)
 
Price: $4.1950 $0.02 0.359%
Day's High: $4.320000171661377 Week Perf: 15.25 %
Day's Low: $ 4.12 30 Day Perf: -4.88 %
Volume (M): 15,222 52 Wk High: $ 5.95
Volume (M$): $ 0 52 Wk Avg: $0.90
Open: $4.26 52 Wk Low: $0.09



 Market Capitalization (Millions $) 4
 Shares Outstanding (Millions) 1
 Employees 1
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Liminatus Pharma, Inc. is a pre-clinical biopharmaceutical company developing cancer therapies that utilize the immune system. Its lead candidate, IBA101, is a humanized anti-CD47 monoclonal antibody targeting advanced solid tumors, including non-small cell lung cancer. IBA101 is designed to block the CD47 "do not eat me" signal on cancer cells to enhance immune recognition and destruction while avoiding anemia and thrombocytopenia. The company intends to initiate clinical trials and expand its portfolio through in-licensing additional therapeutic assets.


   Company Address: 2251 Stern Goodman Street Fullerton 92833 CA
   Company Phone Number: 273-5453   Stock Exchange / Ticker: NASDAQ LIMN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Product Service News

Liminatus Pharma Inc. Exploring New Frontiers with Digital Asset Investment Strategies

Published Fri, Jul 25 2025 12:57 PM UTC

Liminatus Pharma Inc., a firm operating in the pharmaceutical sector, has recently announced its intention to evaluate the formation of a digital asset investment vehicle. This move comes as part of a strategic internal review aimed at diversifying the company’s treasury management and exploring additional capital strategies. The evaluation highlights the growing trend amo...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 13.51
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.99
Working Capital Ratio 1.12
Leverage Ratio (MRQ) 10.32
Total Debt to Equity 4.8
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -23.5 $
Revenues (TTM) -
Cash Flow (TTM) 0.59 $
Cash 3.12 $
Book Value 0.31 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -12,850,522
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.